# Pathos AI **Source:** https://geo.sig.ai/brands/pathos-ai **Vertical:** Healthcare & Life Sciences **Subcategory:** AI Oncology **Tier:** Challenger **Website:** pathos.ai **Last Updated:** 2026-04-14 ## Summary Clinical-stage AI company raised $365M Series D at $1.6B for world's largest multimodal oncology AI; Novo Nordisk partnership; $467M total; combines pathology imaging, genomics, and clinical records to predict treatment responses and guide precision cancer care. ## Company Overview Pathos AI is a clinical-stage AI company building the world's largest multimodal oncology AI platform, combining pathology imaging, genomics, clinical records, and treatment outcome data to power precision cancer care. Founded by oncologists, pathologists, and AI researchers, Pathos has assembled a dataset at a scale that gives its models a meaningful edge: by ingesting vast quantities of multimodal cancer data, its platform can predict treatment responses, identify biomarkers, and guide therapy selection with a level of accuracy that single-modality systems cannot match.\n\nThe platform serves oncologists and cancer centers by providing AI-augmented pathology reads, treatment outcome predictions, and clinical trial matching. Pathos's AI can analyze whole-slide pathology images in combination with molecular and clinical data to generate insights that inform diagnosis and treatment decisions. The company has also built partnerships with pharmaceutical companies — including Novo Nordisk and Prelude Therapeutics — to use its platform for drug development and clinical trial design, adding a biopharma revenue stream alongside its clinical business.\n\nPathos raised $365M in a Series D round at a $1.6B valuation, bringing total funding to $467M. The Series D was one of the largest oncology AI fundraises in history and included backing from top-tier life sciences investors. The Novo Nordisk and Prelude partnerships validate the platform's scientific depth and its utility across both clinical care and drug development. As of 2025–2026, Pathos is advancing toward direct clinical deployment and regulatory submissions, positioning itself as a core infrastructure layer for the future of AI-guided cancer treatment. ## Frequently Asked Questions ### What does Pathos AI do? Pathos AI builds a multimodal oncology AI platform that combines pathology images, genomic data, and clinical records to help oncologists make more accurate treatment decisions. Its AI can predict which therapies a patient's tumor is likely to respond to, augment pathology reads, and match patients to relevant clinical trials — all from a single integrated platform. ### What makes Pathos AI different from other oncology AI companies? Pathos differentiates on data scale and multimodality. Most oncology AI companies analyze a single data type — images or genomics or clinical notes. Pathos integrates all three, which its research shows produces meaningfully better predictions. Its dataset of cancer cases is described as the largest of its kind, giving its models a training advantage that is difficult for smaller entrants to replicate. ### Who has partnered with Pathos AI? Pathos has formed partnerships with Novo Nordisk and Prelude Therapeutics for drug development applications, using its oncology AI platform to support clinical trial design and patient stratification. These biopharma partnerships complement its clinical care business and provide a capital-efficient path to revenue while building the data assets needed for regulatory submissions. ### What is Pathos AI? Pathos AI develops AI systems for oncology drug development — using computational pathology and multimodal AI to analyze tumor biology from pathology images and genomic data, helping identify biomarkers and predict treatment responses. ### What is computational pathology? Computational pathology applies AI and computer vision to digitized tissue slides (whole slide images) — automatically identifying cell types, tumor characteristics, and pathological features that human pathologists currently assess manually with much lower throughput. ### How does Pathos AI help with clinical trials? Pathos AI's biomarker discovery capabilities help pharma companies identify which patient subpopulations respond best to specific treatments — enabling more targeted clinical trials with better patient selection and higher probability of success. ### What type of data does Pathos AI analyze? Pathos AI analyzes whole slide images (histopathology), genomic data, and clinical records in combination — building multimodal AI models that understand cancer biology more holistically than single-data-type approaches. ### Who are Pathos AI's customers? Pathos AI serves pharmaceutical companies and biotech firms conducting oncology drug development — particularly those running clinical trials where better patient stratification and biomarker identification can meaningfully improve trial success rates. ### What is Pathos AI? Pathos AI is an AI-powered oncology platform that uses computational pathology to analyze tumor tissue images and genomic data, providing insights that help predict patient outcomes, stratify clinical trial populations, and accelerate drug development in oncology. ### What is computational pathology and why does Pathos AI use it? Computational pathology applies AI and machine learning to digitized pathology slides (whole slide images) to extract quantitative features invisible to the human eye—such as tumor microenvironment composition, cell morphology patterns, and spatial biomarkers—enabling more precise disease characterization than traditional pathologist review. ### Who are Pathos AI's customers? Pathos AI works with pharmaceutical companies running oncology clinical trials, academic medical centers, and cancer research institutions that need better tools for patient stratification, biomarker discovery, and pathology analysis to accelerate drug development and improve clinical outcomes. ### How does Pathos AI accelerate clinical trials? By applying AI to identify imaging biomarkers that predict drug response or disease progression, Pathos AI helps trial sponsors better select patient populations, identify responders earlier, and generate richer endpoint data—reducing the size, cost, and duration of oncology clinical trials. ### What funding has Pathos AI raised? Pathos AI has raised significant venture funding from healthcare and AI-focused investors. The company positions itself at the intersection of AI and precision oncology, a rapidly growing field as pharmaceutical companies seek computational approaches to improve clinical trial efficiency. ### What does Pathos AI do for oncology drug development? Pathos AI applies artificial intelligence and multi-omics data analysis to accelerate oncology drug discovery and patient stratification. The company builds AI models that integrate genomic, transcriptomic, proteomic, and clinical data to identify biomarker signatures predicting which patients will respond to specific cancer therapies, improving clinical trial design and drug development efficiency. ### How does Pathos AI's platform help pharmaceutical companies design better clinical trials? Pathos AI's patient stratification models identify molecular signatures that predict treatment response, enabling pharma companies to enrich clinical trial populations with patients most likely to benefit. This biomarker-driven patient selection improves trial success rates, reduces development costs, and supports companion diagnostic development for precision oncology therapies. ### What types of cancer does Pathos AI focus on? Pathos AI focuses broadly on solid tumors and hematologic malignancies where multi-omics profiling provides the richest opportunity to identify predictive biomarkers. The company's models are applicable across cancer types and are particularly valuable in immunotherapy development, where predicting responders versus non-responders is an active area of clinical research. ### What data types does Pathos AI integrate in its models? Pathos AI integrates whole-genome sequencing, RNA sequencing, protein expression, methylation data, and clinical outcome data from both clinical trial datasets and real-world oncology data sources. The multi-modal integration captures complementary biological signals that single-omics analysis misses. ### Who are Pathos AI's pharma and biotech partners? Pathos AI works with pharmaceutical companies and biotech firms developing precision oncology therapeutics who need AI-powered biomarker identification and patient stratification capabilities. Partnership deals typically involve milestone payments and data access arrangements where Pathos applies its AI platform to proprietary clinical trial datasets. ## Tags healthtech, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*